Zhao, Kangxian
33  results:
Search for persons X
?
2

Inhibition of Lipopolysaccharide-Induced Inflammatory Bone ..:

Wu, Xinhui ; Zhao, Kangxian ; Fang, Xiaoxin...
Drug Design, Development and Therapy.  15 (2021)  - p. 4741-4757 , 2021
 
?
4

Pristimerin Inhibits Osteoclast Differentiation and Bone Re..:

Sun, Peng ; Yang, Qichang ; Wang, Yanben...
Drug Design, Development and Therapy.  14 (2020)  - p. 4189-4203 , 2020
 
?
6

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis ..:

Peng, Jiaxuan ; Zhao, Kangxian ; Zhu, Jiling...
Drug Design, Development and Therapy.  14 (2020)  - p. 3435-3447 , 2020
 
?
8

Vitexin suppresses RANKL‐induced osteoclastogenesis and pre..:

Jiang, Jiawei ; Jia, Yewei ; Lu, Xuanyuan...
Journal of Cellular Physiology.  234 (2019)  10 - p. 17549-17560 , 2019
 
?
 
?
12

Deguelin inhibits RANKL‐induced osteoclastogenesis in vitro..:

Zhang, Tan ; Zhao, Kangxian ; Han, Weiqi...
Journal of Cellular Physiology.  234 (2018)  3 - p. 2719-2729 , 2018
 
?
13

Garcinol suppresses RANKL‐induced osteoclastogenesis and it..:

Jia, Yewei ; Jiang, Jiawei ; Lu, Xuanyuan...
Journal of Cellular Physiology.  234 (2018)  5 - p. 7498-7509 , 2018
 
?
14

TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-κB s..:

Yang, Wanlei ; Lu, Xuanyuan ; Zhang, Tan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275679/.  , 2021
 
?
15

Inhibition of Lipopolysaccharide-Induced Inflammatory Bone ..:

Wu, Xinhui ; Zhao, Kangxian ; Fang, Xiaoxin...
info:eu-repo/semantics/altIdentifier/doi/10.2147/DDDT.S334421.  , 2021
 
1-15